Phenotypic expression of the p.Leu1077Pro CFTR mutation in Sicilian cystic fibrosis patients

BMC Research Notes

Salvatore Leonardi¹  Mario La Rosa¹  Novella Rotolo¹  Giovanna Di Dio¹  Silvia Cutello¹  Giuseppe Fabio Parisi¹ 

[1] Department of Medical and Pediatric Science, Bronchopneumology and Cystic Fibrosis Unit, University of Catania, Via Santa Sofia 78, Catania 95123, Italy

关键词: Sicilian patients;    Genotype-phenotype;    L1077P;    pLeu1077Pro;    CFTR;    Cystic fibrosis;   

Others  :  1140829
DOI  :  10.1186/1756-0500-6-461

 received in 2013-06-06, accepted in 2013-11-05,  发布年份 2013

【 摘 要 】

Background

The p.Leu1077Pro CFTR mutation was firstly described in 1992 as a mild allele that confers a pancreatic sufficiency phenotype but the information collected in database CFTR2 lead to consider p.Leu1077Pro as a severe CF mutation. Although it is typical of Southern Italy, p.Leu1077Pro is not included in the mutation panel firstly tested in individuals originated from this area. The aim of our study was to describe prevalence and clinical features in patients bearing this mutation followed in our Cystic Fibrosis Centre to demonstrate that this mutation should be included in the mutation panel firstly tested in patients originated from Southern Italy.

Findings

We reviewed data from a cohort of 111 cystic fibrosis patients. 4 patients who were heterozygous for the p.Leu1077Pro mutation were included in the study.

In our Cystic Fibrosis Centre, the prevalence of p.Leu1077Pro is 3.6% among all mutations. All patients had positive sweat test values, pancreatic insufficiency and pulmonary exacerbations. One out of four patients even showed both FEV1 and FVC values significantly below the normal range, the presence of bronchiectasis and chronic Pseudomonas aeruginosa colonization.

Conclusions

We found that the p.Leu1077Pro CFTR mutation is associated with a classic CF phenotype confirming what is reported in CFTR2 database. The relatively high prevalence of p.Leu1077Pro associated with the severe clinical course of the disease in patients bearing this mutation is of interest for genetic counselling purposes, as it should be part of mutation panel to be tested in individuals originated from Southern Italy.

【 授权许可】

   
2013 Parisi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Riordan JR, Rommens JM, Kerem B, et al.: Identification of cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 254:1066-1073.
• [2]Cystic Fibrosis Genetic Database. http://www.genet.sickkids.on.ca/ webcite
• [3]Castellani C, Cuppens H, Macek MJ, et al.: Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008, 7:179-196.
• [4]Rosenstein BJ, Cutting GR: The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998, 132:589-585.
• [5]Knowles MR, Durie PR: Whay is cystic fibrosis? N Engl J Med 2002, 347:439-442.
• [6]De Boeck K, Wilschanski M, Castellani C, et al.: Diagnostic working group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006, 61:627-635.
• [7]Kerem E: Atypical CF, and CF related diseases. Pediatr Respir Rev 2006, 7:S144-S146.
• [8]Bozon D, Zielenski J, Rininsland F, Tsui LC: Identification of Four New Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: I148T, L1077P, Y1092X, 2183AA → G. Human Mutation 1994, 3:330-332.
• [9]Clinical and Functional Translation of CFTR (CFTR2). website. http://www.cftr2.org/ webcite
• [10]Castaldo G, Polizzi A, Tomaiuolo R, et al.: Comprehensive Cystic Fibrosis Mutation Epidemiology and Haplotype Characterization in a Southern Italian Population. Ann Hum Genet 2005, 69:15-24.
• [11]LeGrys VA, Yankaskas JR, Quittel LM, Marshall BC, Mogayzel PJ Jr: Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 2007, 151:85-89.
• [12]American Thoracic S: Standardization of spirometry. 1994 update. Am J Respir Crit Care Med 1995, 152:1107-1136.
• [13]Borowitz D, Baker RD, Stallings V: Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002, 35:246-259.
• [14]Sinaasappel M, Stern M, Littlewood J, et al.: Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002, 1:51-75.
• [15]Williams SG, Evanson JE, Barret N, Hodson ME, Boultbee JE, Westaby D: An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol 1995, 22:513-521.
• [16]Moran A, Hardin D, Rodman D, et al.: Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999, 45:61-73.
• [17]Chehab FF, Wall J: Detection of multiple cystic fibrosis mutations by reverse dot blot hybridization: technology for carrier screening. Hum Genet 1992, 89:163-168.
• [18]Strom CM, Huang D, Chen C, et al.: Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test. Genet Med 2003, 5:9-14.
• [19]McGinniss MJ, Chen C, Redman JB, et al.: Extensive sequencing of the CFTR gene: lessons learned from the first 157 patient samples. Hum Genet 2005, 118:331-338.
• [20]Zielenski J: Genotype and phenotype in cystic fibrosis. Respiration 2000, 67:117-133.
• [21]Scriver CR, Waters PJ: Monogenic traits are not simple: lessons from phenylketonuria. Trend Genet 1999, 15:267-272.
• [22]Davies J, Alton E, Griesenbach U: Cystic fibrosis modifiers genes. J R Soc Med 2005, 98:47-54.